

# Calanolide A



## Drug Description

---

Calanolide A, a novel dipyranocoumarin from the Malaysian tree *Caulophyllum lanigerum* var. *austrocoriaceum*, is a representative of a distinct class of HIV-1 specific nonnucleoside reverse transcriptase inhibitor (NNRTI). Synthetic (+/-)-calanolide A has been chromatographically resolved into its optically active forms. Only the (+)-calanolide A has anti-HIV activity. [1]

## HIV/AIDS-Related Uses

---

Calanolide A is a novel NNRTI with potent in vitro activity against HIV-1 and unique pharmacokinetic properties. In vitro studies have demonstrated the protective activity of calanolide A against a wide variety of HIV-1 isolates, including synctium-inducing and non-synctium-inducing viruses and both T cell tropic and monocyte-macrophage tropic viruses.[2]

## Non-HIV/AIDS-Related Uses

---

Calanolide A may be active against mycobacterium tuberculosis and human cytomegalovirus.[3]

## Pharmacology

---

Calanolide A inhibits HIV-1 but is essentially inactive against HIV-2. Viral life-cycle studies indicated that calanolide A acts early in the infection process, similar to the nucleoside reverse transcriptase inhibitor (NRTI) zalcitabine. In enzyme inhibition assays, calanolide A potently and selectively inhibited recombinant HIV-1 RT but not cellular DNA polymerases or HIV-2 RT.[4]

Evidence suggests that one of the calanolide binding sites is near both the pyrophosphate binding site and the active site of the reverse transcriptase (RT) enzyme.[5]

The safety and pharmacokinetics of a single dose of calanolide A were evaluated in 47 healthy HIV uninfected adult volunteers. Pharmacokinetic parameters were highly variable. The half-life was 20 hours in those receiving an 800 mg dose, indicating that calanolide may be suitable for once-daily dosing. Both the mean maximum

plasma concentration (C<sub>max</sub>) and area under the concentration-time curve (AUC) values increased with the dose. Women appeared to have higher plasma drug levels and a longer elimination half-life than men. However, these differences may be due to differences in body weight. The 50% effective concentration (EC<sub>50</sub>) ranged from 0.02 to 0.5 microM.[6]

In vitro synergy has been demonstrated between calanolide A and NRTIs, NNRTIs, and protease inhibitors. Calanolide A remains fully active against viral isolates with zidovudine and lamivudine resistance mutations.[7] Calanolide A inhibited HIV-1 RT in a synergistic fashion with nevirapine, further distinguishing it from the general class of nonnucleoside RT inhibitors. In vitro studies demonstrated that calanolide A has synergistic anti-HIV activity when used in combination with AZT, nevirapine, ddI, ddC and carbovir.[8]

Calanolide A has enhanced activity against viral isolates with the Y181C mutation, which confers resistance to other NNRTIs. While calanolide A exhibits reduced activity against HIV-1 isolates with the K103N mutation, it remains fully active against viral isolates that express both the K103N and Y181C mutations.[9]

## Adverse Events/Toxicity

---

A phase IA single, escalating-dose study in HIV-1 uninfected participants showed that calanolide A was generally well tolerated in doses up to 800 mg. The most common adverse events observed were an oily aftertaste and mild to moderate dizziness. Headache, eructation, and nausea were also reported; all of these were either mild or moderate. The only significant abnormal laboratory finding was a single report of Grade 3 lipase elevation which was completely asymptomatic and resolved spontaneously.[10]

## Drug and Food Interactions

---

Phase I trials indicate a high degree of variability in the effect of food on the pharmacokinetic profile of calanolide A. Further studies are needed.[11]

# Calanolide A



## Clinical Trials

---

For information on clinical trials that involve Calanolide A, visit the ClinicalTrials.gov web site at <http://www.clinicaltrials.gov>. In the Search box, enter: Calanolide A AND HIV Infections.

## Dosing Information

---

Mode of Delivery: Oral.[12]

Dosage Form: Soft gelatin capsules.[13]

## Chemistry

---

CAS Name: 2H,6H,10H-Benzo(1,2-b:3,4-b':5,6-b') tripyran-2-one, 11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-, (10R-(10alpha,11beta,12alpha))-[14]

CAS Number: 142632-32-4[15]

Molecular formula: C<sub>22</sub>H<sub>26</sub>O<sub>5</sub>[16]

Molecular weight: 370.44[17]

Physical Description: Yellow-brown amorphous solid.[18]

Solubility: Slightly soluble in water. Soluble in methanol, ethanol, and a variety of other organic solvents. Also soluble in vegetable oils and propylene glycol.[19]

## Other Names

---

(+)-Calanolide A[20]

2H,6H,10H-Benzo(1,2-b:3,4-b':5,6-b') tripyran-2-one, 11,12-dihydro-12-hydroxy-6,6,10,11-tetramethyl-4-propyl-, (10R,11S,12S)-[21]

## Further Reading

---

Yu D, Suzuki M, Xie L, Morris-Natschke SL, Lee KH. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. *Med Res Rev*. 2003 May;23(3):322-45.

Eiznhamer DA, Creagh T, Ruckle JL, Tolbert DT, Giltner J, Dutta B, Flavin MT, Jenta T, Xu ZQ.

Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. *HIV Clin Trials*. 2002 Nov-Dec;3(6):435-50.

Hanna L. Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. *BETA*. 1999 Apr;12(2):8-9.

Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, Flavin MT, Xu ZQ. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. *Antimicrob Agents Chemother*. 2001 May;45(5):1379-86.

Buckheit RW Jr, Russell JD, Xu ZQ, Flavin M. Anti-HIV-1 activity of calanolides used in combination with other mechanistically diverse inhibitors of HIV-1 replication. *Antivir Chem Chemother*. 2000 Sep;11(5):321-7.

## Manufacturer Information

---

Calanolide A  
Sarawak MediChem Pharmaceuticals Inc  
12305 South New Ave  
Lemont, IL 60439  
(888) 650-2436

## For More Information

---

Contact your doctor or an AIDSinfo Health Information Specialist:

- Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET
- Via Live Help: [http://aidsinfo.nih.gov/live\\_help](http://aidsinfo.nih.gov/live_help) Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET

# Calanolide A



## References

---

1. J Med Chem - 1996 Mar 15;39(6); p 1303-13
2. Antimicrob Agents Chemother - 2001 May;45(5):1379-86.
3. Sarawak MediChem Pharmaceuticals Inc - Available at: <http://www.sarawak-medicchem.com/>. Accessed 8/11/2003
4. J Pharmacol Exp Ther - 1996 Nov;279(2); p 645-51
5. Antimicrob Agents Chemother - 2001 May;45(5):1379-86
6. Antimicrob Agents Chemother - 2001 May;45(5):1379-86
7. Antivir Ther - 1999;4(4):203-9.
8. J Pharmacol Exp Ther - 1996 Nov;279(2); p 652-61
9. AIDS Clin Care - 1997 Jun;9(6):45-7, 49, 52.
10. Antimicrob Agents Chemother - 2001 May;45(5):1379-86.
11. Antimicrob Agents Chemother - 2001 May;45(5):1379-86.
12. PR Newswire - 1998 Feb 5
13. Sarawak MediChem Pharmaceuticals - Manufacture Contact
14. ChemIDplus. - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 8/11/2003.
15. ChemIDplus. - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 8/11/2003.
16. ChemIDplus. - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed May 15, 2000.
17. NIAID DAIDS Anti-HIV Compounds Database. - Available at: <http://www.niaid.nih.gov/daids/dtpdb/default.htm>. Accessed: June 30, 2000.
18. Sarawak MediChem Pharmaceuticals - Manufacture Contact
19. Sarawak MediChem Pharmaceuticals - Manufacture Contact
20. ChemIDplus. - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 8/11/2003.
21. ChemIDplus. - Available at: <http://chem.sis.nlm.nih.gov/chemidplus/>. Accessed 8/11/2003.